Scientific Reviewer

Cristina Ausin received her Bachelor’s in chemistry and her Masters in chemical engineering from University Ramon Llull in Spain and her Ph.D. in chemistry from the University of Barcelona in Spain

She arrived to the Office of Biotechnology Products in the Food and Drug Administration (FDA) as a post-doctoral fellow in 2004 and spent four years doing research in the oligonucleotide synthesis field. In 2008 she became a researcher reviewer, a full-time reviewer in 2013, and a team lead in 2015. Dr. Ausin joined the Office of Therapeutic Biologics and Biosimilars (OTBB) in FDA in 2018 as a scientific reviewer.